Immunocore Holdings plc (FRA:6YG)
24.00
-1.00 (-4.00%)
Last updated: Jun 3, 2026, 7:55 PM CET
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $106.68M USD in the quarter ending March 31, 2026, with 13.63% growth. This brings the company's revenue in the last twelve months to $412.81M, up 23.75% year-over-year. In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth.
Revenue (ttm)
$412.81M
Revenue Growth
+23.75%
P/S Ratio
3.61
Revenue / Employee
$787.81K
Employees
524
Market Cap
1.29B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 215.75M | 640.71% |
| Dec 31, 2022 | 33.67M | -2.81M | -7.70% |
| Dec 31, 2021 | 36.48M | -4.69M | -11.39% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 635.20M |
| Darwin AG | 54.30M |
| Paion AG | 14.81M |
| 2invest AG | 8.89M |
| MagForce AG | 1.08M |
| Biomark Diagnostics | 57.01K |
| co.don AG | 22.00K |
| bioXXmed AG | 20.49K |
Immunocore Holdings News
- 2 days ago - Immunocore presents updated results from Phase 1/2 trial of brenetafusp - TheFly
- 3 days ago - Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewsWire
- 21 days ago - Immunocore Holdings Slides: Corporate presentation - Filings
- 4 weeks ago - Immunocore reports first quarter financial results and provides a business update - GlobeNewsWire
- 4 weeks ago - Immunocore Holdings Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Immunocore Holdings Earnings release: Q1 2026 - Filings
- 6 weeks ago - Immunocore announces five-year overall survival data for Kimmtrak - TheFly
- 6 weeks ago - KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma - GlobeNewsWire